Table 5.

First-dose Pazopanib Pharmacokinetics in Expanded Cohorts and the Maximum Tolerated Dose (medians and ranges)

Group	Dose (mg)	N	Cmax(µg/mL)	Tmax (hr)	AUC(0–6) (µg/mLxhr)	AUC(0–24) (µg/mLxhr)
A	800	20	30.8 (4.2–66.2)	4.0 (1.(0–24).0)	120.6 (10.8–271.3)	563.1 (74.4–1107)
B	200	1	9.4	6.5	41.8	179.8
	400	1	13.6	2.0	62.0	223.1
	800	6	23.8 (6.1–127.5)	4.6 (2.0–8.3)	103.0 (11.2–403.3)	462.9 (102.0–2147)
C	200	7	4.1 (0.4–13.5)	2.0 (2.0–3.1)	19.7 (1.6–67.1)	42.1 (6.1–231.2)
D	100	3	2.9 (1.8–3.1)	3.0 (2.(0–24).2)	13.1 (0.5–13.3)	33.6 (19.5–43.4)
	200	12	3.7 (0.5–13.1)	3.5 (2.0–8.3)	17.2 (1.8–57.3)	56.4 (6.3–208.4)